Disruptive Anti-Infective Technologies

ContraFect is developing first-in-class biologic therapies for life-threatening, drug-resistant infectious diseases.

News & Events

Oct 4, 2021

ContraFect’s New Phase 2 Exebacase Data Presented at IDWeekTM Demonstrates Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia

Read More »

Sep 29, 2021

ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021

Read More »

See All News & Events »

About

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa.


Learn More »

Media Coverage

ContraFect advancing new modality for antibiotic-resistant infections

BioTuesdays

View »

Lysins Unlimited: Phages’ Secret Weapon

Genetic Engineering & Biotechnology News

View »

The Virtuous Side of Viruses

Scientific American

View »

Leadership

Our leadership team has a track record of creating shareholder value.

Roger J. Pomerantz, M.D., F.A.C.P.

Roger J. Pomerantz, M.D., F.A.C.P.

President, Chief Executive Officer and Chairman of the Board

Dr. Pomerantz has served as Chairman of our board of directors and our Chief Executive Officer since April 2019. Prior to that, he had served as Vice Chairman of our board of directors since May 2014. From November 2013 to Dece...

View Full Profile »
Cara Cassino, M.D.

Cara Cassino, M.D.

Chief Medical Officer and Executive Vice President of Research and Development

Dr. Cassino has served as our Chief Medical Officer since September 2015 and also as Executive Vice President of Research and Development since August 2016. Dr. Cassino has over 20 years of experience as a clinician and executi...

View Full Profile »
Michael Messinger, CPA

Michael Messinger, CPA

Chief Financial Officer

Mr. Messinger has served as our Chief Financial Officer since November 2018. Prior to that, he had served as Vice President of Finance since November 2012. Mr. Messinger has more than 20 years of experience in finance and accou...

View Full Profile »
Natalie Bogdanos J.D.

Natalie Bogdanos J.D.

General Counsel, Corporate Secretary & Data Protection Officer

Ms. Bogdanos has served as our General Counsel and Corporate Secretary since August 2014, and served as our Data Protection Officer since July 2018. She has over 20 years of experience in the legal field, at least 15 of which w...

View Full Profile »
Jane E. Ambler, Ph.D.

Jane E. Ambler, Ph.D.

Vice President of Clinical Microbiology

Dr. Ambler has served as our Vice President of Clinical Microbiology since February 2020. Dr. Ambler has over 25 years of experience working in antibacterial drug development in the pharmaceutical industry and a hospital antibi...

View Full Profile »
Nancy Capra

Nancy Capra

Vice President of Program Management and Development Operations

Ms. Capra has served as our Vice President of Program Management and Development Operations since February 2021. Prior to that, she had served as Executive Director of Program Management since November 2015. Ms. Capra is a Cert...

View Full Profile »
Elsie DiBella, Ph.D.

Elsie DiBella, Ph.D.

Vice President of Manufacturing and Development

Dr. DiBella has served as our Vice President of Manufacturing and Development since March 2021. Dr. DiBella has over 20 years of industry experience in biologics development and manufacturing. Dr. DiBella has worked on over 20 ...

View Full Profile »
Kristina Haeckl, RAC

Kristina Haeckl, RAC

Vice President of Regulatory Affairs and Quality Systems

Ms. Haeckl has served as our Vice President of Regulatory Affairs and Quality Systems since June 2020. She brings over 30 years of experience in global regulatory affairs and quality in the pharmaceutical industry with demonstr...

View Full Profile »
Raymond Schuch, Ph.D.

Raymond Schuch, Ph.D.

Vice President of Research

Dr. Schuch joined ContraFect in 2011 as the VP of Research where his work has supported the continued development of exebacase from IND candidacy through to our ongoing Phase 3 clinical trial. Prior to ContraFect, Dr. Schuch he...

View Full Profile »
David Wilfret, M.D.

David Wilfret, M.D.

Vice President of Clinical Operations

Dr. Wilfret has served as our Vice President of Clinical Operations since February 2021. Dr. Wilfret has over 20 years of experience as a pediatric infectious disease physician and researcher in large pharmaceutical and small b...

View Full Profile »
Gary Woodnutt, Ph.D.

Gary Woodnutt, Ph.D.

Senior Vice President of Translational Sciences and Preclinical Development

Dr. Woodnutt joined ContraFect in June 2021 as the Senior Vice President of Translational Sciences and Preclinical Development. He brings over 30 years of experience leading the discovery and development of innovative therapies...

View Full Profile »
Roger J. Pomerantz, M.D., F.A.C.P.

Roger J. Pomerantz, M.D., F.A.C.P.

President, Chief Executive Officer and Chairman of the Board

Dr. Pomerantz has served as Chairman of our board of directors and our Chief Executive Officer since April 2019. Prior to that, he had served as Vice Chairman of our board of directors since May 2014. From November 2013 to Dece...

View Full Profile »
Sol J. Barer, Ph.D.

Sol J. Barer, Ph.D.

Lead Independent Director

Dr. Barer joined Celanese Research Company in 1974 and formed the Biotechnology Group that was spun out to form Celgene. Dr. Barer was Chairman and Chief Executive Officer from May 1, 2006 until June 16, 2010 and served as Exec...

View Full Profile »
Steven C. Gilman, Ph.D.

Steven C. Gilman, Ph.D.

Vice Chairman of the Board

Dr. Gilman has served on the board of directors since May 2015. He was Chief Executive Officer and Chairman of the board of directors from May 2015 until April 2019. Prior to ContraFect, he served as the Executive Vice Presiden...

View Full Profile »
Cary W. Sucoff, J.D.

Cary W. Sucoff, J.D.

Director

Mr. Sucoff has served as a member of our board of directors since May 2010. Mr. Sucoff has more than 30 years of securities industry experience encompassing supervisory, banking and sales responsibilities. He has participated i...

View Full Profile »
David N. Low, Jr.

David N. Low, Jr.

Director

Mr. Low has served as a member of our board of directors since April 2014. Mr. Low has worked as an investment banker since 1987, with broad investment and advisory experience in the life sciences, biotechnology and medical tec...

View Full Profile »
Michael J. Otto, Ph.D.

Michael J. Otto, Ph.D.

Director

Dr. Otto has served as a member of our board of directors since April 2014. Most recently, he was Chief Scientific Officer of Pharmasset from October 1999 until February 2012, when the company was acquired by Gilead Sciences. H...

View Full Profile »
Lishan Aklog, M.D.

Lishan Aklog, M.D.

Director

Dr. Aklog is Co-Founder, Chairman and Chief Executive Officer of PAVmed Inc. (Nasdaq: PAVM). Dr. Aklog has served as Executive Chairman of Lucid Diagnostics Inc. since its inception in 2018, as a co-founding Partner of both Pav...

View Full Profile »
Jane F. Barlow, MD, MPH, MBA

Jane F. Barlow, MD, MPH, MBA

Director

Dr. Barlow is currently the Chief Executive Officer of Jane Barlow & Associates, LLC, Executive Vice President and Chief Clinical Officer at Real Endpoints. She is a senior advisory to MIT’s Center for Biomedical Innovati...

View Full Profile »

Annaliesa Anderson, PhD, FAAM

Science & Technology Committee Observer

Dr. Anderson is an Observer on our Science & Technology Committee.  She has over 20 years of pharmaceutical research and development experience and is currently the Vice President and Chief Scientific Officer for Bacte...

View Full Profile »

Stock Information Data is 15 minutes delayed

ContraFect Corporation — Common Stock Nasdaq: CFRX
Price
Change
Market Cap
Volume
View Our

SEC Filings